Review article: The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 1, 2001, Pages 1-9

  Hawkey, C J ^a   Jackson, L ^a   Harper, S E ^b   Simon, T J ^b   Mortensen, E ^b   Lines, C R ^b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG EFFECT; DRUG SAFETY; DRUG TOLERANCE; HUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; ENZYME INHIBITORS; HUMANS; INTESTINAL PERFORATION; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; OSTEOARTHRITIS; PEPTIC ULCER; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES;

EID: 0035176616     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.00894.x     Document Type: Review

References (30)

1. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use
2. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
3. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy
4. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
5. Overview - Mechanisms of action of anti-inflammatory drugs
6. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
7. COX-2 inhibitors
8. The discovery of rofecoxib Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone, an orally active cyclooxygenase-2-inhibitor
9. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
10. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs. ibuprofen in patients with osteoarthritis
11. Characterization of rofecoxib as a cyclooxygense-2 isoform inhibitor and demonstration of analgesia in the dental pain model
12. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial
13. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
14. 2) synthesis in healthy humans
15. Evidence that the COX-2 specific inhibitor rofecoxib at 50 mg spares gastric mucosal prostaglandin synthesis in humans
16. Demonstration of specific COX-2 inhibition by MK-966 (VIOXX) in humans with supratherapeutic doses
17. The pathogenesis and consequence of non steroidal anti-inflammatory drug induced small intestinal inflammation in man
18. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects. A double-blind, crossover study comparing rofecoxib with placebo and indomethacin
19. Gastrointestinal microbleeding: Comparisons between benoxaprofen and other nonsteroidal antiinflammatory agents
20. Fecal blood loss after specific inhibition of cyclooxygenase-2: Treatment with rofecoxib compared with ibuprofen and placebo
21. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa
22. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
23. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
24. A randomized, double-blinded comparison of the effect of rofecoxib (a drug specifically inhibiting COX-2), ibuprofen, or placebo on the gastroduodenal mucosa of osteoarthritis patients
25. Effect of rofecoxib on endoscopic ulcers in osteoarthritis patients: Analysis of potential risk factors
26. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats
27. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
28. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
29. Treatment with rofecoxib required less gastrointestinal (GI) co-medication and fewer GI procedures than non-specific cyclooxygenase inhibitors (NSAIDs)